1318027-24-5

Basic information

• Product Name: (3AR,4S,7R,7aS)-hexahydro-4,7-Methano-2H-isoindole-1,3-dione
• Synonyms: (3AR,4S,7R,7aS)-hexahydro-4,7-Methano-2H-isoindole-1,3-dione
• CAS NO: 1318027-24-5
• Molecular Formula: C9H11NO2
• Molecular Weight: 165.18914
• Mol File: 1318027-24-5.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3AR,4S,7R,7aS)-hexahydro-4,7-Methano-2H-isoindole-1,3-dione(CAS DataBase Reference)
• NIST Chemistry Reference: (3AR,4S,7R,7aS)-hexahydro-4,7-Methano-2H-isoindole-1,3-dione(1318027-24-5)
• EPA Substance Registry System: (3AR,4S,7R,7aS)-hexahydro-4,7-Methano-2H-isoindole-1,3-dione(1318027-24-5)

Safety Data

• Hazardous Substances Data: 1318027-24-5(Hazardous Substances Data)

Usage

Description

(3aR,4S,7R,7aS)-Hexahydro-4,7-methano-2H-isoindole-1,3-dione, also known as phthalimide, is a white crystalline compound commonly used in the synthesis of various pharmaceuticals. It is a cyclic imide containing a six-membered ring with nitrogen atoms at positions 1 and 3, and a carbonyl group at position 2.
Used in Pharmaceutical Industry:
Phthalimide is used as a precursor in the synthesis of various pharmaceuticals due to its ability to form stable intermediates and facilitate the synthesis of complex molecules.
Used in Agrochemical Industry:
Phthalimide is used as a precursor for the synthesis of agrochemicals, herbicides, and fungicides, contributing to the development of effective crop protection products.
Used in Electronics Industry:
Phthalimide is used as a monomer in the production of polyimide resins, which have high thermal stability and are commonly used as insulating materials in the electronics industry.
Used in Organic Chemistry:
Phthalimide is used in the synthesis of various cyclic compounds and as a building block in organic chemistry, enabling the creation of diverse chemical structures for research and industrial applications.

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 129-64-6 3,6-endomethylene-1,2,3,6-tetrahydrophthalic anhydride 
• 6265-30-1 (1R,2S,6R,7S)-4-azatricyclo[5.2.1.0(2,6)]dec-8-ene-3,5-dione 
• 542-92-7 cyclopenta-1,3-diene 
• 2746-19-2 (1R,2R,6S,7S)-4-oxa-tricyclo[5.2.1.0^2,6]dec-8-ene-3,5-dione 
• 14166-28-0 exo-bicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride 
• 17812-27-0 cis-5-norbornene-endo-2,3-dicarboxylic anhydride 

Downstream Products

• 367514-88-3 (3aR,4S,7R,7aS)-2-[((1R,2R)-2-{[4-(l1,2-benzisothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl)methyl]hexahydro-1H-4,7-methanisoindol-1,3-dione hydrochloride 
• 1318074-18-8 C₂₈H₃₆N₄O₂S 
• 194861-74-0 lurasidone 
• 194861-74-0 [14C]-Lurasidone 

Relevant articles and documents

Succinimide derivatives. II. Synthesis and antipsychotic activity of N- [4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]1,2-cis- cyclohexanedicarboximide (SM-9018) and related compounds

Cyclic imides bearing ω-(4-benzisothiazol-3-yl-1-piperazinyl)alkyl moieties were synthesized and tested for antipsychotic activity. The in vitro binding affinities of these compounds were examined for dopamine 2 (D2) and serotonin 2 (5-HT2) receptor sites. Structure-activity relationships within these series are discussed. One of these compounds, N-[4-[4-(1,2- benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cis-cyclohexanedicarboximide (SM-9018), was found to be more potent and more selective in vivo than tiospirone in its antipsychotic activity. SM-9018 (17) is currently undergoing clinical evaluation as a selective antipsychotic agent.

IBX-mediated oxidation of unactivated cyclic amines: application in highly diastereoselective oxidative Ugi-type and aza-Friedel-Crafts reactions

The first o-iodoxybenzoic acid (IBX) mediated oxidation of unactivated amines to imines is described. A range of meso-pyrrolidines were shown to be suitable substrates. The chemical space was further explored with one-pot oxidative Ugi-type and aza-Friedel-Crafts reactions, which proved to be highly diastereoselective.

INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF

The present invention relates to a process for the preparation of Lurasidone or a pharmaceutically acceptable salt thereof, a compound useful for the treatment of schizophrenia and bipolar disorder. The present invention further relates to processes for the preparation of Lurasidone intermediates, and to certain novel intermediates obtained by such processes.